Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: A report of the working party of the british society for antimicrobial chemotherapy

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 269-289

  Gould, F Kate ^a   Denning, David W ^b   Elliott, Tom S J ^c   Foweraker, Juliet ^d   Perry, John D ^a   Prendergast, Bernard D ^e   Sandoe, Jonathan A T ^f   Spry, Michael J ^a   Watkin, Richard W ^g  

^a FREEMAN HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d PAPWORTH HOSPITAL   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^g UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antimicrobial therapy; Enterococci; Fungal infections; Staphylococci; Streptococcus spp.

Indexed keywords

AMOXICILLIN; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CEFTRIAXONE; CIPROFLOXACIN; DAPTOMYCIN; DOXYCYCLINE; FLUCLOXACILLIN; FLUCONAZOLE; FLUCYTOSINE; GENTAMICIN; HYDROXYCHLOROQUINE; ITRACONAZOLE; MEROPENEM; MICAFUNGIN; PENICILLIN G; POSACONAZOLE; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN; VORICONAZOLE;

ADULT DISEASE; ANIMAL MODEL; ANTIBIOTIC THERAPY; ASPERGILLOSIS; ASPERGILLUS ENDOCARDITIS; BACTERIAL ENDOCARDITIS; BARTONELLOSIS; CANDIDA ENDOCARDITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; CONSENSUS DEVELOPMENT; DISEASE PREDISPOSITION; DRUG FEVER; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ENDOCARDITIS; ENTEROCOCCAL ENDOCARDITIS; ENTEROCOCCAL INFECTION; EVIDENCE BASED PRACTICE CENTER; FUNGAL ENDOCARDITIS; HEART SURGERY; HEART VALVE; HUMAN; IN VITRO STUDY; MEDICAL SOCIETY; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MYOSITIS; NATIVE VALVE ENDOCARDITIS; NEUTROPENIA; NONHUMAN; PRACTICE GUIDELINE; PROSTHETIC VALVE ENDOCARDITIS; PUBLICATION; Q FEVER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTIC SHOCK; SEROLOGY; STAPHYLOCOCCAL ENDOCARDITIS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCAL ENDOCARDITIS; STREPTOCOCCUS INFECTION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG THERAPY; ENDOCARDITIS; HUMANS; MYCOSES;

EID: 84855860437     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr450     Document Type: Review

References (137)

1. Elliott TS, Foweraker J, Gould FK et al. Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2004; 54: 971-81.
2. Prendergast BD. The changing face of infective endocarditis. Heart 2006; 92: 879-85.
3. Murdoch DR, Corey GR, Hoen B et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009; 169: 463-73.
4. Perez de Isla L, Zamorano J, Lennie V et al. Negative blood culture infective endocarditis in the elderly: long-term follow-up. Gerontology 2007; 53: 245-9.
5. National Institute for Health and Clinical Excellence. Guideline 64. Prophylaxis against Infective Endocarditis: Antimicrobial Prophylaxis against Infective Endocarditis in Adults and Children Undergoing Interventional Procedures. March 2008. http://www.nice.org.uk/ nicemedia/pdf/CG64NICEguidance.pdf (15 September 2011, date last accessed).
6. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994; 96: 200-9.
7. Sachdev M, Peterson GE, Jollis JG. Imaging techniques for diagnosis of infective endocarditis. Infect Dis Clin North Am 2002; 16: 319-37.
8. Greaves K, Mou D, Patel A et al. Clinical criteria and the appropriate use of transthoracic echocardiography for the exclusion of infective endocarditis. Heart 2003; 89: 273-5.
9. Petti CA, Fowler VG Jr. Staphylococcus aureus bacteremia and endocarditis. Cardiol Clin 2003; 21: 219-33.
10. Prendergast BD. Diagnostic criteria and problems in infective endocarditis. Heart 2004; 90: 611-3.
11. Fournier PE, Casalta JP, Habib G et al. Modification of the diagnostic criteria proposed by the Duke Endocarditis Service to permit improved diagnosis of Q fever endocarditis. Am J Med 1996; 100: 629-33.
12. Li JS, Sexton DJ, Mick N et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633-8.
13. Department of Health (UK). Taking Blood Cultures: A Summary of Best Practice. http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@ dh/@en/documents/digitalasset/dh_078118.pdf (15 September 2011, date last accessed).
14. Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis 2007; 45: S177-83.
15. Blot F, Nitenberg G, Chachaty E et al. Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet 1999; 354: 1071-7.
16. Horstkotte D, Follath F, Gutschik E et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the Task Force of the European Society of Cardiology. Eur Heart J 2004; 25: 267-76.
17. Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis 2005; 41: 1677-80.
18. Weinstein MP. Emerging data indicating that extended incubation of blood cultures has little clinical value. Clin Infect Dis 2005; 41: 1681-2.
19. Petti CA, Bhally HS, Weinstein MP et al. Utility of extended blood culture incubation for isolation of Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella organisms: a retrospective multicenter evaluation. J Clin Microbiol 2006; 44: 257-9.
20. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48 Suppl 1: 5-16.
21. Kugler KC, Biedenbach DJ, Jones RN. Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms. Diag Microbiol Infect Dis 1999; 34: 73-6.
22. Houpikian P, Raoult D. Diagnostic methods. Current best practices and guidelines for identification of difficult-to-culture pathogens in infective endocarditis. Cardiol Clin 2003; 21: 207-17.
23. Raoult D, Fournier PE, Drancourt M et al. Diagnosis of 22 new cases of Bartonella endocarditis. Ann Intern Med 1996; 125: 646-52.
24. Watkin RW, Lang S, Lambert PA et al. The microbial diagnosis of infective endocarditis. J Infect 2003; 47: 1-11.
25. Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. Clin Microbiol Rev 2001; 14: 177-207.
26. Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. Medicine (Baltimore) 2005; 84: 162-73.
27. Maurin M, Eb F, Etienne J et al. Serological cross-reactions between Bartonella and Chlamydia species: implications for diagnosis. J Clin Microbiol 1997; 35: 2283-7.
28. Inan MB, Eyileten ZB, Ozcinar E et al. Native valve Brucella endocarditis. Clin Cardiol 2010; 33: E20-6.
29. Calabrese F, Carturan E, Thiene G. Cardiac infections: focus on molecular diagnosis. Cardiovasc Pathol 2010; 19: 321-5.
30. Muñoz P, Bouza E, Marín M et al. Heart valves should not be routinely cultured. J Clin Microbiol 2008; 46: 2897-901.
31. Lang S, Watkin RW, Lambert PA et al. Evaluation of PCR in the molecular diagnosis of endocarditis. J Infect 2004; 48: 269-75.
32. Millar BC, Moore JE. Current trends in the molecular diagnosis of infective endocarditis. Eur J Clin Microbiol Infect Dis 2004; 23: 353-65.
33. Breitkopf C, Hammel D, Scheld HH et al. Impact of a molecular approach to improve the microbiological diagnosis of infective heart valve endocarditis. Circulation 2005; 111: 1415-21.
34. Kotilainen P, Heiro M, Jalava J et al. Aetiological diagnosis of infective endocarditis by direct amplification of rRNA genes from surgically removed valve tissue. An 11-year experience in a Finnish teaching hospital. Ann Med 2006; 38: 263-73.
35. Marín M, Muñoz P, Sánchez M et al. Molecular diagnosis of infective endocarditis by real-time broad-range polymerase chain reaction (PCR) and sequencing directly from heart valve tissue. Medicine (Baltimore) 2007; 86: 195-202.
36. Voldstedlund M, Nørum Pedersen L, Baandrup U et al. Broad-range PCR and sequencing in routine diagnosis of infective endocarditis. APMIS 2008; 116: 190-8.
37. Madico GE, Rice PA. 16S-ribosomal DNA to diagnose culture-negative endocarditis. Curr Infect Dis Rep 2008; 10: 280-6.
38. Lang S, Watkin RW, Lambert PA et al. Detection of bacterial DNA in cardiac vegetations by PCR after the completion of antimicrobial treatment for endocarditis. Clin Microbiol Infect 2004; 10: 579-81.
39. Rovery C, Greub G, Lepidi H et al. PCR detection of bacteria on cardiac valves of patients with treated bacterial endocarditis. J Clin Microbiol 2005; 43: 163-7.
40. Fenollar F, Gauduchon V, Casalta JP et al. Mycoplasma endocarditis: two case reports and a review. Clin Infect Dis 2004; 38: e21-4.
41. Vollmer T, Piper C, Horstkotte D et al. 23S rDNA real-time polymerase chain reaction of heart valves: a decisive tool in the diagnosis of infective endocarditis. Eur Heart J 2010; 31: 1105-13.
42. Rice PA, Madico GE. Polymerase chain reaction to diagnose infective endocarditis: will it replace blood cultures? Circulation 2005; 111: 1352-4.
43. Casalta JP, Gouriet F, Roux V. Evaluation of the LightCycler SeptiFast test in the rapid etiologic diagnostic of infectious endocarditis. Eur J Clin Microbiol Infect Dis 2009; 28: 569-73.
44. Fenollar F, Fournier PE, Raoult D. Molecular detection of Coxiella burnetii in the sera of patients with Q fever endocarditis or vascular infection. J Clin Microbiol 2004; 42: 4919-24.
45. Fenollar F, Raoult D. Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. Int J Antimicrob Agents 2007; 30 Suppl 1: S7-15.
46. Syed FF, Millar BC, Prendergast BD. Molecular technology in context: a current review of diagnosis and management of infective endocarditis. Prog Cardiovasc Dis 2007; 50: 181-97.
47. Lepidi H, Durack DT, Raoult D. Diagnostic methods-current best practices and guidelines for histologic evaluation in infective endocarditis. Infect Dis Clin North Am 2002; 16: 339.
48. Greub G, Lepidi H, Rovery C et al. Diagnosis of infectious endocarditis in patients undergoing valve surgery. Am J Med 2005; 118: 230-8.
49. Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2009; 30: 2369-413.
50. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394-434.
51. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44: 1208-15.
52. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009; 53: 4069-79.
53. Trcka J, Seitz CS, Brocker EB et al. Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin. J Antimicrob Chemother 2007; 60: 107-11.
54. Francioli PB, Stamboulian D. Outpatient treatment of infective endocarditis. Clin Microbiol Infect 1998; 4 Suppl 3: S47-55.
55. Stamboulian D, Bonvehi P, Arevalo C et al. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Reviews Infect Dis 1991; 13 Suppl 2: 160-3.
56. Francioli P, Etienne J, Hoigne R et al. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. JAMA 1992; 267: 264-7.
57. Venditti M, Gelfusa V, Serra P et al. 4-Week treatment of streptococcal native valve endocarditis with high-dose teicoplanin. Antimicrob Agents Chemother 1992; 36: 723-6.
58. Chu VH, Cabell CH, Benjamin DK et al. Early predicators of in-hospital death in infective endocarditis. Circulation 2004; 109: 1745-9.
59. Cosgrove SE, Vigliani GA, Fowler VG Jr et al. Initial low-dose gentamicin for Staphylococcus aureus bacteraemia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48: 713-21.
60. Riedel DJ, Weekes E, Forrest GN. Addition of rifampicin to standard therapy for treatment of native valve endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2462-7.
61. Bayer AS, Lam K. Efficacy of vancomycin plus rifampicin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis 1985; 151: 157-65.
62. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampicin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Int Med 1991; 115: 674-80.
63. Fowler VG, Boucher HD, Corey GR. Daptomycin versus standard therapy for bacteraemia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
64. Cubicin (daptomycin for injection) for the treatment of Staphylococcus aureus bacteraemia including those with known or suspected infective endocarditis http://www.fda.gov/ohrms/DOCKETS/ac/06/briefing/2006-4209B1_02_01-FDA-Background.pdf (15 September 2011, date last accessed).
65. Twele L, Moyen E, Zhang K et al. Methicillin-resistant Staphylococcus aureus endocarditis and de novo development of daptomycin resistance during therapy. Can J Infect Dis Med Microbiol 2010; 21: 89-93.
66. Cunha BA, Pherez FM. Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE). Eur J Clin Microbiol Infect Dis 2009; 28: 831-3.
67. Sakoulas G, Rose W, Rybak MJ et al. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nanosusceptibility to daptomycin. J Clin Microbiol 2008; 46: 220-4.
68. Kirby A, Mohandas K, Broughton C et al. In vivo development of heterogenous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis. J Med Microbiol 2009; 58: 376-80.
69. Tenover FC, Sinner SW, Segal RE et al. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int J Antimicrob Agents 2009; 33: 564-8.
70. Hirschwerk D, Ginocchio CC, Bythrow M et al. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteraemia. Infect Control Hosp Epidemiol 2006; 27: 315-7.
71. Murthy M, Olson ME, Wickert RW et al. Daptomycin non-susceptible methicillin-resistant Staphylococcus aureus USA 300 isolate. J Med Microbiol 2008; 57: 1036-8.
72. Sharma M, Riederer K, Chase P et al. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis 2008; 27: 433-7.
73. Sandoe J, Baig W. Daptomycin use for endocardial infection in Leeds, UK. In: Abstracts Infection 2009. Birmingham, UK.
74. Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a b-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006; 57: 639-47.
75. Buchholtz K, Larsen CT, Hassager C et al. Severity of gentamicin's nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. Clin Infect Dis 2009; 48: 65-71.
76. Brown DF, Hope R, Livermore DM et al. Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62 Suppl 2: ii75-85.
77. Levy CS, Kogulan P, Gill VJ et al. Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Clin Infect Dis 2001; 33: 577-9.
78. Knoll B, Tleyjeh IM, Steckelberg JM et al. Infective endocarditis due to penicillin-resistant viridans group streptococci. Clin Infect Dis 2007; 44: 1585-92.
79. Zheng X, Freeman AF, Villafranca J et al. Antimicrobial susceptibilities of invasive pediatric Abiotrophia and Granulicatella isolates. J Clin Microbiol 2004; 42: 4323-6.
80. Senn L, Entenza JM, Greub G et al. Bloodstream and endovascular infections due to Abiotrophia defectiva and Granulicatella species. BMC Infect Dis 2006; 6: 9.
81. Lin CH, Hsu RB. Infective endocarditis caused by nutritionally variant streptococci. Am J Med Sci 2007; 334: 235-9.
82. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009; 48: 1596-600.
83. Martinez E, Miro JM, Almirante B et al. Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults. Clin Infect Dis 2002; 35: 130-9.
84. Martinez F, Martin-Luengo F, Garcia A et al. Treatment with various antibiotics of experimental endocarditis caused by penicillin-resistant Streptococcus sanguis. Eur Heart J 1995; 16: 687-91.
85. Hsu RB, Lin FY. Effect of penicillin resistance on presentation and outcome of nonenterococcal streptococcal infective endocarditis. Cardiology 2006; 105: 234-9.
86. Levitz RE. Prosthetic-valve endocarditis caused by penicillin-resistant Streptococcus mitis. N Engl J Med 1999; 340: 1843-4.
87. McDonald JR, Olaison L, Anderson DJ et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am J Med 2005; 118: 759-66.
88. Olaison L, Schadewitz K. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002; 34: 159-66.
89. Jayaprakash K, Abdul Khadar S, Thoams JK et al. An amazing dance across the aortic valve. Int J Cardiol 2009; 134: 70-2.
90. Gavalda J, Len O, Miro JM et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007; 146: 574-9.
91. Tascini C, Dona R, Leonildi A et al. Efficacy of the combination ampicillin plus ceftriaxone in the treatment of a case of enterococcal endocarditis due to Enterococcus faecalis highly resistant to gentamicin: efficacy of the 'ex vivo' synergism method. J Antimicrob Chemother 2004; 16: 400-3.
92. Singh A. Ampicillin plus ceftriaxone for high-level aminoglycoside-resistant Enterococcus faecalis endocarditis-author reply. Ann Int Med 2008; 148: 243.
93. Wareham DW, Abbas H, Karher AM et al. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. J Infect 2006; 52: 300-4.
94. Archuleta S, Murphy B, Keller MJ. Successful treatment of vancomycin-resistant Enterococcus faecium endocarditis with linezolid in a renal transplant recipient with human immunodeficiency virus infection. Transpl Infect Dis 2004; 6: 117-9.
95. Berdal JE, Eskesen A. Short-term success, but long-term treatment failure with linezolid for enterococcal endocarditis. Scand J Infect 2008; 40: 765-6.
96. Tsigrelis C, Singh KV, Coutinho TD et al. Vancomycin-resistant Enterococcus faecalis endocarditis linezolid failure and strain characterisation of virulence factors. J Clin Microbiol 2007; 45: 631-5.
97. Cunha BA, Mickonil N, Eisenstein L. E. faecalis vancomycin-sensitive enterococcal bacteraemia unresponsive to a vancomycin-tolerant strain successfully treated with high-dose daptomycin. Heart Lung 2007; 36: 456-61.
98. Akins RL, Haase MR, Levy EN. Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis. Pharmacotherapy 2006; 26: 694-8.
99. Schwartz BS, Ngo PD, Guglielmo BJ. Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding? Ann Pharmacother 2008; 42: 289-90.
100. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of Gram-positive bacteraemia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006; 26: 347-52.
101. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med 2007; 120: 528-33.
102. Hidron AI, Schuetz AN, Nolte FS et al. Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis. J Antimicrob Chemother 2008; 61: 1394-6.
103. Patel R, Rouse MS, Piper KE et al. Linezolid treatment of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob Agents Chemother 2001; 45: 621-3.
104. Vouillamoz J, Moreillon P, Giddey M et al. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug resistant enterococci. J Antimicrob Chemother 2006; 58: 1208-14.
105. Cabell CH, Abrutyn E. Progress toward a global understanding of infective endocarditis. Early lessons from the International Collaboration on Endocarditis investigation. Infect Dis Clin North Am 2002; 16: 255-72.
106. Das M, Badley AD, Cockerill FR et al. Infective endocarditis caused by HACEK microorganisms. Am Rev Med 1997; 48: 25-33.
107. Raoult D, Houpikian P, Tissot DH et al. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Int Med 1999; 159: 167-73.
108. Palmer SR, Young SE. Q-fever endocarditis in England and Wales, 1975-81. Lancet 1982; 2: 1448-9.
109. Connolly JH, Coyle PV, Adget AA et al. Clinical Q fever in Northern Ireland 1962-1989. Ulster Med J 1990; 59: 137-44.
110. Brouqui P, Dupont HT, Drancourt M et al. Chronic Q fever. Ninety-two cases from France, including 27 cases without endocarditis. Arch Int Med 1993; 153: 642-8.
111. Raoult D, Marrie TJ, Mege JL. Natural history and pathophysiology of Q fever. Lancet Infect Dis 2005; 5: 219-26.
112. Siegman-Igra Y, Kaufman O, Keysary A et al. Q fever endocarditis in Israel and a worldwide review. Scand J Infect Dis 1997; 29: 41-9.
113. Fenollar F, Thuny F, Xeridat B et al. Endocarditis after acute Q fever in patients with previously undiagnosed valvulopathies. Clin Infect Dis 2006; 42: 818-21.
114. Raoult D, Tissot-Dupont H, Foucault C et al. Q fever 1985-1998. Clinical and epidemiologic features of 1,383 infections. Medicine 2000; 79: 109-23.
115. Lecaillet A, Mallet MN, Raoult D et al. Therapeutic impact of the correlation of doxycycline serum concentrations and the decline of phase I antibodies in Q fever endocarditis. J Antimicrob Chemother 2009; 63: 771-4.
116. Rolain JM, Boulos A, Mallet M-N et al. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob Agents Chemother 2005; 49: 2673-6.
117. Rolain JM, Brouqui P, Koehler JE et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48: 1921-33.
118. Raoult D, Fournier PE, Vandenesch F et al. Outcome and treatment of Bartonella endocarditis. Arch Int Med 2003; 163: 226-30.
119. Maurin M, Birtles R, Raoult D. Current knowledge of Bartonella species. Eur J Clin Microbiol Infect Dis 1997; 16: 487-506.
120. Drancourt M, Mainardi JL, Brouqui P et al. Bartonella (Rochalimaea) quintana endocarditis in three homeless men. N Engl J Med 1995; 332: 419-23.
121. Breathnach AS, Hoare JM, Eykyn SJ. Culture-negative endocarditis: contribution of Bartonella infections. Heart 1997; 77: 474-6.
122. Fournier PE, Lelievre H, Eykyn SJ. Epidemiologic and clinical characteristics of Bartonella quintana and Bartonella henselae endocarditis: a study of 48 patients. Medicine 2001; 80: 245-51.
123. Pendle S, Ginn A, Iredell J. Antimicrobial susceptibility of Bartonella henselae using Etest methodology. J Antimicrob Chemother 2005; 57: 761-3.
124. Reyes MP, Reyes KC. Gram-negative endocarditis. Curr Infect Dis Rep 2008; 10: 267-74.
125. Falcone M, Barzaghi N, Carosi G et al. Italian Study on Endocarditis. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine 2009; 88: 160-8.
126. Ellis ME, Al-Abdely H, Sandridge A et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32: 50-62.
127. McCormack J, Pollard J. Aspergillus endocarditis 2003-2009. Med Mycol 2011; 49 Suppl 1: S30-4.
128. Jensen J, Guinea J, Torres-Narbona M et al. Post-surgical invasive aspergillosis: an uncommon and under-appreciated entity. J Infect 2010; 60: 162-7.
129. Levy I, Shalit I, Birk E et al. Candida endocarditis in neonates: report of five cases and review of the literature. Mycoses 2006; 49: 43-8.
130. Baddley JW, Benjamin DK Jr, Patel M et al. International Collaboration on Endocarditis-Prospective Cohort Study Group (ICE-PCS). Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008; 27: 519-29.
131. Pappas PG, Kauffman CA, Andes D et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
132. Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997; 41: 13-6.
133. Flückiger U, Marchetti O, Bille J et al. Fungal Infection Network of Switzerland (FUNGINOS). Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006; 136: 447-63.
134. Walsh TJ, Anaissie EJ, Denning DW et al. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
135. Böhme A, Ruhnke M, Buchheidt D et al. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
136. Bhatti S, Vilenski L, Tight R et al. Histoplasma endocarditis: clinical and mycologic features and outcomes. J Infect 2005; 51: 2-9.
137. Lyratzopoulos G, Ellis M, Nerringer R et al. Invasive infection due to Penicillium species other than P. marneffei. J Infect 2002; 45: 184-95.